Xenon Pharmaceuticals to Participate in the 12th Annual Wedbush PacGrow Healthcare Conference
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced its participation in the 12th Annual Wedbush PacGrow Healthcare Conference. The company will engage in one-on-one investor meetings and a virtual panel discussion titled “Got My Mind Set On You - Advancing Novel Epilepsy Targets.”
The panel is scheduled for August 11, 2021, from 11:30 am to 12 pm Eastern Time, featuring Dr. Simon Pimstone, Executive Chair of the Board. Interested parties can find further details and a link to the live webcast on the Investors section of Xenon's website.
- None.
- None.
Insights
Analyzing...
BURNABY, British Columbia, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its participation in one-on-one investor meetings as well as a virtual panel discussion at the 12th Annual Wedbush PacGrow Healthcare Conference.
Panel Topic: | “Got My Mind Set On You - Advancing Novel Epilepsy Targets” |
Date: | Wednesday, August 11, 2021 |
Time: | 11:30 am – 12 pm Eastern Time |
Panelist: | Dr. Simon Pimstone, Executive Chair of the Board |
Additional details along with a link to the live webcast can be found on the “Investors” section of Xenon’s website at http://investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event for 30 days. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Maria McClean
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com
